Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks and is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients and is under Phase 1 clinical trial. It operates in the Netherlands, Switzerland, and the United States. The company was incorporated in 2015 and is based in Leiden, the Netherlands.

Pharvaris N.V.

Pharvaris is a clinical-stage company focused on bringing oral bradykinin-B2-receptor antagonists to patients. By targeting this clinically proven therapeutic target with novel small molecules, the Pharvaris team is advancing new alternatives to injected therapies for all sub-types of HAE and other bradykinin-mediated diseases. The company brings together executives with a breadth of expertise across pharmaceutical development and rare disorders, including HAE.

The company reunites the core team responsible for the discovery and approval of the HAE treatment icatibant. With novel small molecules, we have identified and are advancing potent, orally available compounds targeting this clinically proven therapeutic target.


Bain Capital Life Sciences

Foresite Capital

General Atlantic

venBio Partners

Venrock Healthcare Capital Partners

Kurma Partners

Venrock

Cormorant Asset Management

Viking Global Investors

Pharvaris

The Pharvaris team is onsite at the Consortium of Independent Immunology Clinics (CIIC) Spring 2024 Meeting in Arlington, TX. Visit us at our booth and connect with our team Kenneth Robinson Amy DeWerth Wim Souverijns #HAE #deucrictibant #drugdevelopment

This afternoon, Pharvaris reported our fourth quarter and full year 2023 financial results and provided a business update. Highlights include enrollment in RAPIDe-3, scheduling an End-of-Phase 2 meetings to discuss development plan of deucrictibant for the prophylaxis of HAE attacks, strengthening the executive committee, and receipt of the UK Innovation Passport. #clinicaltrials #newhires #therapeuticinnovation 

Read the full press release here: https://lnkd.in/e2zGM6HB

Welcome, David Nassif, to the Pharvaris team! In the role of Chief Financial Officer, Mr. Nassif will be responsible for refining and implementing Pharvaris’ corporate #financialstrategy and activities including #financial #reporting and #operations. Mr. Nassif joins Pharvaris with more than 30 years of experience in financial #management, #strategicplanning, #mergersandacquisitions, #investorrelations, #legal, and #capitalallocation, having held multiple executive financial management roles in development-stage, commercial-stage, public and private companies. Read the full press release here: https://lnkd.in/eRfP54vz

Stefan Abele, Pharvaris' Chief Technical Operations Officer and member of the board of the Division of Industrial and Applied Chemistry (DIAC) of the Swiss Chemical Society (SCS), recently published an open-access article in the Journal of the German Chemical Society GDCh. The article conveys the dynamic industry-academia ecosystem in Switzerland and displays DIAC's outreach and scope to spark inspiration. Read it here: https://lnkd.in/e-TzMbCQ or here: https://lnkd.in/gqPEg6hG

The Pharvaris team is looking forward to connecting with the HAE community at the Consortium of Independent Immunology Clinics (CIIC) Spring 2024 Conference in Arlington, TX. Please feel free to connect with Kenneth Robinson, Amy DeWerth, or Wim Souverijns on site at our booth. Find more details on our #deucrictibant data presentation here: https://lnkd.in/eXCHS_jr

	Dec '18	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
revenue
cost of revenue		547.41 -		80.46K -	150.19K 86.67%	252.27K 67.97%
gross profit		-547.41 -		-80.46K -	-150.19K 86.67%	-252.27K 67.97%
selling and marketing expenses
general and administrative expenses	668.12K -	2.33M 248.10%	5.50M 136.42%	18.35M 233.72%	29.34M 59.89%
selling general and administrative expenses	668.12K -	2.33M 248.10%	5.50M 136.42%	18.35M 233.72%	29.34M 59.89%	30.44M 3.77%
research and development expenses	3.65M -	5.68M 55.94%	19.51M 243.18%	35.79M 83.46%	57.38M 60.32%	64.23M 11.95%
other expenses
cost and expenses	4.31M -	8.01M 85.70%	25.01M 212.18%	54.14M 116.50%	86.71M 60.17%	94.93M 9.47%
operating expenses	4.31M -	8.01M 85.70%	25.01M 212.18%	54.14M 116.50%	86.71M 60.17%	94.67M 9.18%
interest expense			92.47K -	278.18K 200.83%	16.11K 94.21%	20.05K 24.53%
ebitda	-4.31M -	-7.99M 85.30%	-25.01M 212.85%	-65.82M 163.23%	-86.58M 31.54%	-94.67M 9.34%
operating income	-4.31M -	-7.99M 85.31%	-25.01M 212.92%	-65.90M 163.46%	-86.74M 31.62%	-94.93M 9.44%
depreciation and amortization		549 -	7.40K 1,248.09%	77.37K 945.40%	152.94K 97.67%	252.27K 64.95%
total other income expenses net	-380 -	-33.76K 8,784.74%	-1.06M 3,028.24%	23.24M 2,300.29%	11.08M 52.30%	-2.85M 125.74%
income before tax	-4.31M -	-8.03M 86.08%	-26.07M 224.76%	-42.66M 63.65%	-75.65M 77.34%	-97.78M 29.25%
income tax expense	380 -	16.88K 4,342.37%	-83.25K 593.16%	70.12K 184.22%	679.09K 868.51%	1.03M 51.28%
net income	-4.31M -	-8.04M 86.45%	-25.99M 223.04%	-42.73M 64.44%	-76.33M 78.64%	-98.81M 29.44%
weighted average shs out	31.84M -	4.85M 84.77%	30.52M 529.26%	30.41M 0.35%	33.59M 10.44%	38.39M 14.31%
weighted average shs out dil	31.84M -	4.85M 84.77%	30.52M 529.26%	30.41M 0.35%	33.59M 10.44%	38.39M 14.31%
eps	-0.14 -	-1.66 1,085.71%	-0.85 48.80%	-1.41 65.88%	-2.27 60.99%	-2.57 13.22%
epsdiluted	-0.14 -	-1.66 1,085.71%	-0.85 48.80%	-1.41 65.88%	-2.27 60.99%	-2.57 13.22%

NASDAQ:PHVS

Pharvaris

Last Close

17.44

26/07 20:00

Market Cap

953.63M

Beta: −4.61

Volume Today

35.62K

Avg: 20.88K

PE Ratio

−14.74

PFCF: −13.89

Preview